3 Trending Biotech Stocks To Watch On Monday
CORAL GABLES, FL / ACCESSWIRE / October 9, 2017 / Here are three trending biotech stocks to watch during Monday's trading session:
GT Biopharma Inc. (GTBP), a targeted immunotherapies company with near market treatments for Central Nervous System diseases, has made several key announcements leading up to this month. The company announced the closing of a merger with Georgetown Translational Pharmaceuticals Inc. They also announced the new addition to their executive team, hiring Dr. Raymond Urbanski as their new Chief Medical Officer. Dr. Urbanksi comes to GT Biopharma after serving as CMO for Pfizer for eight years.
"My rise at Pfizer was rapid, as I went from a Medical Director to the Head of a business unit at the largest pharmaceutical company in the world in under 4 years. I have been involved in all phases of drug development, from discovery through FDA phase 4 clinical trials and fast to market FDA 505 (b)(2) licenses. This included an abundance of Oncology assets," Dr. Urbanski stated. "I believe it is my breadth of knowledge, experience, and proven record of success that brings true value to GT Biopharma."
Since the start of the month, GTBP has been trading between the price range $5.00 and $5.40.
Biostar Pharmaceuticals Inc. (BSPM) is a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China. During Monday (10/9/17) morning's trading session, shares of BSPM hiked 66.44%, from lows of $1.52 to intraday highs of $2.53.
MannKind Corporation (MNKD), a biotech company that focuses on the development and commercialization of Afrezza®, an inhalation powder has been on a tear since the start of October. Shares of MNKD have jumped 172.13% from the start of October, from lows of $2.01 to pre-market highs during Monday's (10/9/17) trading session of $5.47.
This surge comes on the heels of the company's most recent announcement, stating that the FDA has approved three changes to the label for Afrezza®. The CEO, Michael Castagna, stated this was "a pivotal moment in the history of the company."
About BiotechStocks.com
BIOTECHSTOCKS.com (BTS) is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by GT Biopharma Inc. for a period beginning August 1, 2017 and ending Oct. 1, 2017, now extended to November 1, 2017, to publicly disseminate information about GTBP. Full Disclaimer Here.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com.
NO WARRANTY
BTS, the Author, and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Contact:
SOURCE: BiotechStocks.com
